Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Mental health conditions 

Poor evidence available on cannabinoids in mental health conditions

Researchers identified 83 studies reporting the effects of cannabinoids in several mental health conditions and found a lack of high-quality evidence supporting their use.

cannabis marijuana medical bedrocan

Source: Shutterstock.com

Several countries have legalised the use of medical cannabinoids for certain conditions, although a lack of high-quality evidence exists for their use in mental health conditions

There is a lack of high-quality evidence supporting the use of cannabinoids in the treatment of mental disorders, the authors of a meta-analysis published in the Lancet Psychiatry have concluded (28 October 2019)[1].

The researchers identified 83 studies which reported the effects of cannabinoids — including pharmaceutical cannabinoids and their synthetic derivatives — in depression, anxiety, attention-deficit hyperactivity disorder, Tourette’s syndrome, post-traumatic stress disorder and psychosis.

Few randomised controlled trials examined the role of pharmaceutical cannabidiol or medicinal cannabis.

Overall, the researchers found there was no impact of cannabinoid treatment on any of the conditions. They also noted that most of the available data came from trials where mental disorders were not the primary condition being studied.

There was evidence that tetrahydrocannabinol improved anxiety symptoms in people with other conditions, including chronic pain and multiple sclerosis, but the quality of the evidence was low.

The team said that the findings were important given that several countries have now legalised the use of medical cannabinoids.

Louisa Degenhardt, lead author and researcher from the University of New South Wales, Australia, said: “Doctors and patients must be aware of the limitations of existing evidence and the risks of cannabinoids. These must be weighed when considering use to treat symptoms of common mental health disorders.” 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207406

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.